Finance

Lists
Outlook: 46.0% bullish·1.1% bearish
Go to analysis
PFE:NYSE
Pfizer Inc
$29.23
0.00%
(0.00) 1D
Nov 10, 12:43:06 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PFE...
Open
$29.15
High
$29.29
Low
$28.95
Mkt. cap
166.61B
Avg. vol.
34.32M
Volume
11.92M
Dividend
5.88%
Quarterly dividend
$0.43
Ex-dividend date
Nov 6, 2026
P/E ratio
41.80
52-wk high
$31.44
52-wk low
$23.62
EPS
$0.70
Beta
0.31
Shares outstanding
5.70B
No. of employees
75K
Open
$29.15
High
$29.29
Low
$28.95
Mkt. cap
166.61B
Avg. vol.
34.32M
Volume
11.92M
Dividend
5.88%
Quarterly dividend
$0.43
Ex-dividend date
Nov 6, 2026
P/E ratio
41.80
52-wk high
$31.44
52-wk low
$23.62
EPS
$0.70
Beta
0.31
Shares outstanding
5.70B
No. of employees
75K
News stories
From web sources and news partners
Profile
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America. Pfizer develops and produces medication and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company's largest products by sales are Eliquis, Prevnar, Paxlovid, Vyndaqel, Comirnaty, and Ibrance. In 2025, 59% of the company's revenues came from the United States, 5% came from China, and 36% came from other countries. The company is ranked fifth on the list of largest biomedical companies by revenue. It is ranked the 69th on the Fortune 500 and 73rd on the Forbes Global 2000. Wikipedia
About Pfizer Inc
CEOAlbert Bourla
Employees75K
Founded1849
HeadquartersNew York, New York, United States
Sector-
Industry-
Websitepfizer.com
Analyst ratings
Based on 22 analysts giving stock ratings to PFE in the past 3 months
Hold
Buy
6
Hold
15
Sell
1
12-month forecast
Based on 22 Wall Street analysts offering 12 month price targets for PFE in the last 3 months.
Highest
Current $29.23
$36.00 (+23.16%)
Average
$30.28 (+3.59%)
Lowest
$25.00 (-14.47%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ilya Zubkov
Freedom Capital Markets
Buy
Maintained
$34.00
+16.3%
11/06/2026
Elmar Kraus
DZ BANK AG
Hold
Downgraded
-
-
11/05/2026
Vamil Divan
Guggenheim
Buy
Maintained
$33.00
+12.9%
11/04/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$35.00
+19.7%
11/04/2026
Jason Gerberry
Bank of America Securities
Hold
Reiterated
-
-
11/04/2026
Asad Haider
Goldman Sachs
Hold
Maintained
$28.00
-4.2%
11/04/2026
Carter Gould
Cantor Fitzgerald
Hold
Maintained
$28.00
-4.2%
11/03/2026
Michael Yee
UBS
Hold
Maintained
$30.00
+2.6%
11/04/2026
Louise Chen
Scotiabank
Buy
Maintained
$35.00
+19.7%
11/04/2026
Trung Huynh
RBC Capital
Hold
Reiterated
$28.00
-4.2%
11/03/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$26.00
-11.1%
11/04/2026
Geoff Meacham
Citi
Hold
Maintained
$30.00
+2.6%
11/04/2026
Mohit Bansal
Wells Fargo
Hold
Reiterated
$28.00
-4.2%
11/04/2026
Akash Tewari
Jefferies
Buy
Maintained
$36.00
+23.2%
11/03/2026
Chris Schott
J.P. Morgan
Hold
Maintained
$30.00
+2.6%
11/03/2026
Emily Field
Barclays
Sell
Maintained
$25.00
-14.5%
11/03/2026
Courtney Breen
Bernstein
Hold
Maintained
$29.00
-0.8%
10/25/2026
Kerry Holford
Berenberg Bank
Hold
Maintained
$25.00
-14.5%
10/20/2026
Luisa Hector
Berenberg Bank
Hold
Maintained
$25.00
-14.5%
10/20/2026
Derek Archila
Wells Fargo
Hold
Maintained
$28.00
-4.2%
10/16/2026
Nico Chen
DBS
Buy
Maintained
$35.00
+19.7%
10/08/2026
Unknown Analyst
Leerink Partners
Hold
Maintained
-
-
10/02/2026
Rajesh Kumar
HSBC
Hold
Maintained
$30.00
+2.6%
09/10/2026
Steve Scala
TD Cowen
Hold
Maintained
-
-
08/11/2026
Jill Wu
CMB International Securities
Buy
Maintained
$35.75
+22.3%
08/07/2026
David Toung
Argus Research
Buy
Maintained
-
-
08/05/2026
Alexandria Hammond
Wolfe Research
Sell
Reiterated
$26.00
-11.1%
05/13/2026
Hans Engel
Erste Group
Hold
Maintained
-
-
05/05/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
04/27/2026
Narumi Nakagiri
Daiwa
Hold
Downgraded
$27.00
-7.6%
02/12/2026
Last report
Nov 3, 2026
Fiscal period
Q3 2026
$0.87 / $0.74
+18.26%beat
Revenue / Est. (USD)
16.58B / 15.86B
+4.54%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
17.56B
14.45B
15.03B
16.58B
Cost of goods sold
5.06B
3.41B
3.66B
3.84B
Cost of revenue
5.06B
3.41B
3.66B
3.84B
Research and development expenses
3.32B
2.45B
2.75B
2.96B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.74B
2.84B
3.26B
3.12B
Operating expense
8.29B
6.48B
7.19B
7.20B
Total operating expenses
13.35B
9.88B
10.84B
11.05B
Operating income
4.20B
4.57B
4.19B
5.54B
Other non operating income
1.35B
36.00M
515.00M
349.00M
EBT including unusual items
-1.64B
3.17B
-653.00M
3.39B
EBT excluding unusual items
5.09B
4.13B
4.25B
5.39B
Income tax expense
-2.00M
461.00M
-407.00M
134.00M
Effective tax rate
0.12%
14.55%
62.33%
3.96%
Other operating expenses
-
-
-
-
Net income
-1.65B
2.69B
-248.00M
3.24B
Net profit margin
-9.39%
18.59%
-1.65%
19.55%
Earnings per share
0.66
0.75
0.77
0.87
Interest and investment income
247.00M
197.00M
211.00M
166.00M
Interest expense
-711.00M
-668.00M
-667.00M
-662.00M
Net interest expenses
-464.00M
-471.00M
-456.00M
-496.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
5.86B
6.18B
5.80B
7.10B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps